JP5460594B2 - ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 - Google Patents

ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 Download PDF

Info

Publication number
JP5460594B2
JP5460594B2 JP2010520238A JP2010520238A JP5460594B2 JP 5460594 B2 JP5460594 B2 JP 5460594B2 JP 2010520238 A JP2010520238 A JP 2010520238A JP 2010520238 A JP2010520238 A JP 2010520238A JP 5460594 B2 JP5460594 B2 JP 5460594B2
Authority
JP
Japan
Prior art keywords
treatment
disorder
escitalopram
pharmaceutical composition
cariprazine hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010520238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535790A5 (cg-RX-API-DMAC10.html
JP2010535790A (ja
Inventor
ニカ・アダム
ゲイリー・サモリスキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2010535790A publication Critical patent/JP2010535790A/ja
Publication of JP2010535790A5 publication Critical patent/JP2010535790A5/ja
Application granted granted Critical
Publication of JP5460594B2 publication Critical patent/JP5460594B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010520238A 2007-08-03 2008-08-04 ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 Active JP5460594B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95369407P 2007-08-03 2007-08-03
US60/953,694 2007-08-03
PCT/US2008/072066 WO2009020897A1 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands

Publications (3)

Publication Number Publication Date
JP2010535790A JP2010535790A (ja) 2010-11-25
JP2010535790A5 JP2010535790A5 (cg-RX-API-DMAC10.html) 2011-09-22
JP5460594B2 true JP5460594B2 (ja) 2014-04-02

Family

ID=40338740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520238A Active JP5460594B2 (ja) 2007-08-03 2008-08-04 ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法

Country Status (20)

Country Link
US (3) US20090036468A1 (cg-RX-API-DMAC10.html)
EP (1) EP2185155B1 (cg-RX-API-DMAC10.html)
JP (1) JP5460594B2 (cg-RX-API-DMAC10.html)
KR (1) KR101612563B1 (cg-RX-API-DMAC10.html)
CN (1) CN101815519B (cg-RX-API-DMAC10.html)
AU (1) AU2008283989B2 (cg-RX-API-DMAC10.html)
CA (1) CA2695519A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119828T1 (cg-RX-API-DMAC10.html)
DK (1) DK2185155T3 (cg-RX-API-DMAC10.html)
EA (1) EA018064B1 (cg-RX-API-DMAC10.html)
ES (1) ES2653852T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171908T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036004T2 (cg-RX-API-DMAC10.html)
LT (1) LT2185155T (cg-RX-API-DMAC10.html)
MY (1) MY157192A (cg-RX-API-DMAC10.html)
NO (1) NO2185155T3 (cg-RX-API-DMAC10.html)
PL (1) PL2185155T3 (cg-RX-API-DMAC10.html)
PT (1) PT2185155T (cg-RX-API-DMAC10.html)
SI (1) SI2185155T1 (cg-RX-API-DMAC10.html)
WO (1) WO2009020897A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY156288A (en) 2008-07-16 2016-01-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
WO2011060363A2 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
MX390264B (es) * 2010-06-18 2025-03-20 Takeda Pharmaceuticals Co Antagonistas d2, metodos de sintesis y metodos de uso.
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) * 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US12433904B2 (en) 2019-04-17 2025-10-07 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
GEAP202416526A (en) * 2021-10-28 2024-09-25 Richter Gedeon Nyrt Treatment of major depressive disorder
CA3240774A1 (en) * 2021-12-13 2023-06-22 Compass Pathfinder Limited Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
CN119136804A (zh) * 2022-03-17 2024-12-13 Mapi医药公司 包含卡利拉嗪或其盐的储库系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6556540B1 (en) * 1998-05-29 2003-04-29 Paradyne Corporation System and method for non-intrusive measurement of service quality in a communications network
HK1043129B (zh) * 1999-10-25 2004-10-21 H‧隆德贝克有限公司 西酞普蘭的製備方法
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
JP2004527551A (ja) * 2001-05-01 2004-09-09 ハー・ルンドベック・アクチエゼルスカベット エナンチオ純粋なエスシタロプラムの使用方法
WO2003086393A1 (en) * 2002-04-12 2003-10-23 Sepracor, Inc. 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods of use thereof
JP2005533069A (ja) * 2002-06-20 2005-11-04 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤を使用する組み合わせ治療法
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
KR20060072127A (ko) * 2003-09-04 2006-06-27 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 억제제 및 록사핀의 조합
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása

Also Published As

Publication number Publication date
MY157192A (en) 2016-05-13
EA201000280A1 (ru) 2010-08-30
CA2695519A1 (en) 2009-02-12
HRP20171908T1 (hr) 2018-01-26
HK1144784A1 (en) 2011-03-11
AU2008283989A1 (en) 2009-02-12
US20110015208A1 (en) 2011-01-20
SI2185155T1 (en) 2018-02-28
US20090036468A1 (en) 2009-02-05
CY1119828T1 (el) 2018-06-27
KR20100059830A (ko) 2010-06-04
EP2185155A4 (en) 2012-04-25
NO2185155T3 (cg-RX-API-DMAC10.html) 2018-03-03
ES2653852T3 (es) 2018-02-09
EA018064B1 (ru) 2013-05-30
EP2185155B1 (en) 2017-10-04
LT2185155T (lt) 2017-12-11
WO2009020897A1 (en) 2009-02-12
JP2010535790A (ja) 2010-11-25
PT2185155T (pt) 2018-01-04
PL2185155T3 (pl) 2018-03-30
DK2185155T3 (en) 2018-01-02
HUE036004T2 (hu) 2018-06-28
US20120028991A1 (en) 2012-02-02
CN101815519A (zh) 2010-08-25
KR101612563B1 (ko) 2016-04-14
AU2008283989B2 (en) 2013-12-05
EP2185155A1 (en) 2010-05-19
CN101815519B (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
JP5460594B2 (ja) ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法
JP6668045B2 (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
KR102527805B1 (ko) 부스피론 대사물의 용도
Marcus et al. Augmentation by escitalopram, but not citalopram or R‐citalopram, of the effects of low‐dose risperidone: Behavioral, biochemical, and electrophysiological evidence
KR20180015158A (ko) L-４-클로로키누레닌의 치료적 용도
US20120046302A1 (en) Methods of treating cns disorders
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
JP5736175B2 (ja) 精神障害の治療に有用なα−アミノアミド誘導体
JP2020075933A (ja) ストレス性疾患の予防および／または治療用医薬
WO2010126527A1 (en) Methods of treating cns disorders
JP2007504181A (ja) セロトニン再取り込み阻害剤およびロキサピンの併用
HK1144784B (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
Hutson et al. The effects in rats of lisdexamfetamine in combination with olanzapine on mesocorticolimbic dopamine efflux, striatal dopamine D2 receptor occupancy and stimulus generalization to a D-amphetamine cue
Nishino et al. Overview of management of narcolepsy
JP2017057188A (ja) 特別な形態のてんかんの併用療法
JP2022534973A (ja) 自閉症スペクトラム障害を治療するための選択的ヒスタミンｈ３受容体アンタゴニスト
Shaw et al. Psychopharmacology in the physically ill child
Monti et al. Role of zolpidem in the management of primary and comorbid insomnia
JP2007504180A (ja) セロトニン再取り込み阻害剤およびアモキサピンの併用
KR20100022956A (ko) 급성 조증 치료용 카르바모일-시클로헥산
HK1116664A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130730

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140114

R150 Certificate of patent or registration of utility model

Ref document number: 5460594

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250